secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001510964-23-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q3 revenue $4.1M (+9% YoY); margin expands; signs LOI for European acquisition
--------------------------------------------------------------------------------

- Revenue $4.1M, +9% YoY from $3.8M; gross margin 45.1% vs 41.6%.
- Operating loss narrowed to $0.4M from $0.9M; adjusted EBITDA -$0.4M vs -$1.2M.
- Cash balance $1.6M (up from $0.6M end 2022); operating cash flow $2.4M (incl. $2.5M ERC).
- Signed non-binding LOI to acquire a plant-based food company in Europe as part of new M&A strategy.
- Maintained #1 hemp extract brand in natural retail; launched PlusCBD Reserve Sleep Gummies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000151096423000036/0001510964-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000151096423000036/cvsi-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001510964-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer